COMP <GO>
SYK vs UNH // REVENUE GROWTH (YOY)
Stryker Corporation (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: SYK 7
— UNH 8
▲ REVENUE GROWTH (YOY) LEADER: SYK
LAST: $291.86 (-6.38%) • MKT CAP: $119.58B
revenue-growth
11.20%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYK VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYK | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.00% | 88.57% | -24.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.60% | 11.47% | +0.13 | SYK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 23.6x | 16.4x | +7.15 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 3.58% | 6.48% | -2.90 | UNH | /fcf-yield <GO> |
| Operating Margin | 19.50% | 4.82% | +14.68 | SYK | /operating-margins <GO> |
| Net Profit Margin | 12.90% | 3.14% | +9.76 | SYK | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 11.20% | 6.46% | +4.74 | SYK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.07% | 2.28% | -1.21 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.46 | 3.12 | +1.34 | SYK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | SYK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.74% | +0.56 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 56.0 | -8.07 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.33 | +0.80 | SYK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.2x | 17.1x | +17.11 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $119.58B | $364.66B | -$245.08B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYK REV | UNH REV | SYK GROSS % | UNH GROSS % | SYK FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $25.12B | $447.57B | 64.0% | 88.7% | $4.28B | $16.07B |
| FY 2024 | $22.59B | $400.28B | 63.9% | 88.3% | $3.49B | $20.70B |
| FY 2023 | $20.50B | $371.62B | 44.0% | 89.6% | $2.79B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYK // BETA 1.13
UNH // BETA 0.33